CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Sees Significant Increase in Short Interest

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 267,900 shares, an increase of 229.9% from the June 30th total of 81,200 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is presently 0.2 days. Approximately 9.7% of the company’s shares are sold short.

Hedge Funds Weigh In On CNS Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC raised its stake in CNS Pharmaceuticals by 616.6% in the first quarter. Virtu Financial LLC now owns 94,246 shares of the company’s stock worth $34,000 after buying an additional 81,094 shares in the last quarter. Smith Anglin Financial LLC bought a new position in CNS Pharmaceuticals in the fourth quarter worth about $64,000. Finally, Armistice Capital LLC bought a new position in CNS Pharmaceuticals in the fourth quarter worth about $155,000. 14.02% of the stock is owned by institutional investors.

CNS Pharmaceuticals Stock Up 4.6 %

Shares of NASDAQ:CNSP traded up $0.05 during midday trading on Thursday, hitting $1.13. 727,794 shares of the stock traded hands, compared to its average volume of 731,414. The stock has a market capitalization of $1.63 million, a PE ratio of -0.01 and a beta of 2.61. The business’s 50 day moving average is $4.49 and its two-hundred day moving average is $13.47. CNS Pharmaceuticals has a one year low of $1.00 and a one year high of $137.50.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($20.50) EPS for the quarter.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.